<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080444</url>
  </required_header>
  <id_info>
    <org_study_id>0869-097</org_study_id>
    <secondary_id>Formerly-0304AHEC</secondary_id>
    <secondary_id>MK-0869-097</secondary_id>
    <secondary_id>2004_099</secondary_id>
    <nct_id>NCT00080444</nct_id>
  </id_info>
  <brief_title>Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Emetogenic Chemotherapy in Adolescent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and
      vomiting caused by emetogenic cancer chemotherapy in adolescent participants. Participants
      treated with emetogenic cancer chemotherapies that include either cisplatin,
      cyclophosphamide, or carboplatin, or participants who experienced nausea and/or vomiting when
      treated with a previously administered chemotherapy regimen that is planned to be repeated
      will be enrolled in this study. In the double-blind Part 1 of this study, enrolled
      participants will be randomized to receive either aprepitant or standard therapy. In Part 2
      of this study, enrolled participants will receive open-label aprepitant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of treatment is the first 4 days of one 28-day cycle (Cycle 1). Participants who
      successfully complete Cycle 1 may be eligible to participate for 9 subsequent optional,
      open-label, 28-day cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycle 1)</measure>
    <time_frame>Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience a Complete Response (CR) to Anti-emetic Therapy (Cycle 1)</measure>
    <time_frame>Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Absence of Nausea (Cycle 1)</measure>
    <time_frame>Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Absence of Vomiting (Cycle 1)</measure>
    <time_frame>Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Serious Adverse Events (Cycles 2-10)</measure>
    <time_frame>Up to 14 days after last dose of anti-emetic therapy in Cycles 2-10 (Up to 10.5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycles 2-10)</measure>
    <time_frame>Up to 14 days after last dose of anti-emetic therapy in Cycles 2-10 (Up to 10.5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycles 2-10)</measure>
    <time_frame>Up to Day 4 of Cycles 2-10 (Up to 10 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Serious Adverse Events (Cycle 1)</measure>
    <time_frame>Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience Serious Study-drug-related Adverse Events (Cycle 1)</measure>
    <time_frame>Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycle 1)</measure>
    <time_frame>Up to Day 4 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aprepitant Plasma Drug Concentration Profiles and Pharmacokinetics</measure>
    <time_frame>Up to 24 hours after first dose of aprepitant</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Part 1: Aprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>aprepitant capsules</description>
    <arm_group_label>Part 1: Aprepitant</arm_group_label>
    <arm_group_label>Part 2: Aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>ondansetron IV preparation</description>
    <arm_group_label>Part 1: Aprepitant</arm_group_label>
    <arm_group_label>Part 1: Standard Therapy</arm_group_label>
    <arm_group_label>Part 2: Aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>dexamethasone tablets</description>
    <arm_group_label>Part 1: Aprepitant</arm_group_label>
    <arm_group_label>Part 1: Standard Therapy</arm_group_label>
    <arm_group_label>Part 2: Aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to aprepitant</intervention_name>
    <description>Matching placebo to aprepitant capsules</description>
    <arm_group_label>Part 1: Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to dexamethasone</intervention_name>
    <description>Matching placebo to dexamethasone tablets</description>
    <arm_group_label>Part 1: Aprepitant</arm_group_label>
    <arm_group_label>Part 2: Aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rescue medication</intervention_name>
    <description>Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.</description>
    <arm_group_label>Part 1: Aprepitant</arm_group_label>
    <arm_group_label>Part 1: Standard Therapy</arm_group_label>
    <arm_group_label>Part 2: Aprepitant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cycle 1: Participant is to be treated with an emetogenic chemotherapy regimen that
             includes either cisplatin, cyclophosphamide, or carboplatin, for a documented
             malignancy. OR Participant did not tolerate a previously administered chemotherapy
             regimen, for a documented malignancy, secondary to nausea and/or vomiting that is
             planned to be repeated.

          -  Cycle 1: Participant has Karnofsky score ≥60

          -  Cycle 1: Participant has a predicted life expectancy of ≥3 months

        Exclusion Criteria:

          -  Cycle 1: Participant will receive stem cell rescue therapy in conjunction with course
             of chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B; Adolescent Aprepitant in Cancer Study Group. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009 Feb;52(2):242-7. doi: 10.1002/pbc.21811.</citation>
    <PMID>18985740</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2004</study_first_submitted>
  <study_first_submitted_qc>April 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2004</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

